timothy sykes logo
MYGN Stock Slides As Myriad Genetics Slashes 2026 Outlook Thumbnail
G Google News

MYGN Stock Slides As Myriad Genetics Slashes 2026 Outlook

ELLIS HOBBS•UPDATED AUG. 1, 2026, 10:07 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Myriad Genetics Inc. stocks have been trading down by -45.72 percent amid heightened concern over its latest clinical trial setback.

What Traders Need To Know

  • Guidance for FY26 revenue was cut to $770M-$790M from $860M-$880M, well under prior consensus near $863.6M, signaling a meaningful reset in growth expectations.
  • Management kept adjusted gross margin guidance at 66%-67%, suggesting pricing and cost control remain relatively stable despite weaker top-line trends.
  • TD Cowen lowered its price target from $6 to $4 and kept a Hold rating, flagging weak Q2 results, more payer friction, and soft prenatal demand.
  • Shares fell from above $5 to under $3 in days, showing aggressive repricing as traders digested the guidance cut and analyst downgrade.

Candlestick Chart

Weekly Update Jul 27 – Jul 31, 2026: On Saturday, August 01, 2026 Myriad Genetics Inc. stock [NASDAQ: MYGN] is trending down by -45.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

Myriad Genetics sits in a challenged but asset-rich position within molecular diagnostics. Revenue of ~$825M growing mid‑single digits and a 70% gross margin underscore a solid top line and pricing power, yet EBIT margin of roughly -47% and ROE near -77% highlight structurally unprofitable operations. Cash of ~$115M, current ratio 2.4, and debt-to-equity 0.63 provide adequate near-term liquidity. A 0.57x price-to-sales and 1.4x book valuation reflect clear market skepticism but also deep turnaround optionality.

Technically, MYGN is in a pronounced downtrend. The stock broke from the mid-$5s to sub-$3 in days, with successive lower highs and a sharp expansion in intraday ranges, indicating capitulation selling on elevated volume. The critical actionable level is $3.50: it now acts as overhead resistance after the breakdown from the $5–$6 congestion zone. Below, $2.75 is the key downside reference; only sustained closes back above $3.50 justify short covering or tactical long entries.

Fundamentally, guidance cuts (FY26 revenue now $770M–$790M vs prior $860M–$880M) and payer friction put Myriad’s growth and scale thesis behind sector peers in Healthcare and especially Medical Diagnostics & Screening, where many competitors generate positive operating leverage at similar or lower multiples. With deteriorating sentiment and a TD Cowen target of $4, MYGN trades as a high‑risk turnaround. Fair risk‑adjusted range is $2.50–$4.00 over 12 months, with resistance at $3.50 and support near $2.75.

More Breaking News

Quick Financial Overview

Myriad Genetics Inc. sits at an awkward spot where revenue scale and margins look solid on paper, but profitability is deeply negative. Over the last quarter, the company generated about $190.7M in revenue with a gross margin near 70%, yet still posted a net loss of $43.2M. That flows through to an EBITDA loss of $26.1M and negative earnings per share of -$0.46, which traders cannot ignore in a higher-rate market that punishes unprofitable names.

The balance sheet provides some breathing room. Myriad Genetics Inc. holds roughly $115.2M in cash and cash equivalents, working capital around $158.3M, and a current ratio of 2.4, which signals near-term obligations are covered. Long-term debt of about $203.2M and total liabilities of $335M are meaningful but not extreme against $638.9M in total assets. Still, key return metrics are sharply negative, with return on equity and return on assets both deeply below zero, showing capital is not yet earning its keep.

Price action is where the story turns urgent for traders. In late July 2026, MYGN traded above $5, then broke sharply: a drop from $5.71 to $3.35, and then to roughly $2.91, is a major sentiment shift in just a few sessions. Intraday, a 5-minute bar showing a range from $3.26 down to $2.81 with a close near $2.86 reflects heavy intraday selling pressure and failed bounces. With guidance for FY26 revenue now reset to $770M-$790M, well below prior $860M-$880M and consensus around $863.6M, this chart is telling you the market is rapidly pricing in slower growth and higher risk.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”